Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Phathom Pharmaceuticals Inc
Cash Equivalents
Phathom Pharmaceuticals Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
Cash Equivalents
$381.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
235%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Equivalents
$3.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Pfizer Inc
NYSE:PFE
|
Cash Equivalents
$719m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is Phathom Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
381.4m
USD
Based on the financial report for Dec 31, 2023, Phathom Pharmaceuticals Inc's Cash Equivalents amounts to 381.4m USD.
What is Phathom Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
235%
Over the last year, the Cash Equivalents growth was 145%. The average annual Cash Equivalents growth rates for Phathom Pharmaceuticals Inc have been 10% over the past three years , 235% over the past five years .